R&D News | pharmaphorum

News

GSK sets up Nucala and Dupixent showdown in COPD

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.

News

US is planning $500m project on 'universal vaccines;' WSJ

The US will spend $500m to develop universal vaccines against multiple virus variants, while planned changes to testing rules are raising concerns.

News

Senator Susan Collins, chair of the Appropriations Committee

Senior Republican hits out at Trump's research funding cuts

The Republican chair of the Appropriations Committee has slammed the Trump administration for actions that are putting US biomedical research at risk.

News

Shreeram Aradhye, Novartis' chief medical officer

Novartis grabs kidney drug developer Regulus in $1.7bn deal

Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.

News

AstraZeneca's Discovery Centre in Cambridge

AZ backs up threat of manufacturing shift from Europe

AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.

News

Belén Garijo, Merck's chair and chief executive

Merck agrees $3.9 billion takeover of SpringWorks

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.

GSK sets up Nucala and Dupixent showdown in COPD

US is planning $500m project on 'universal vaccines;' WSJ

Senior Republican hits out at Trump's research funding cuts

Novartis grabs kidney drug developer Regulus in $1.7bn deal

AZ backs up threat of manufacturing shift from Europe

Merck agrees $3.9 billion takeover of SpringWorks

Sanofi eyeing pipeline deals ahead of Dupixent patent loss

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks